Stevanato Group S.p.A. (STVN)
NYSE: STVN · Real-Time Price · USD
21.99
-0.63 (-2.79%)
At close: Aug 25, 2025, 4:00 PM
21.94
-0.05 (-0.23%)
After-hours: Aug 25, 2025, 7:00 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
Biopharmaceutical and Diagnostic Solutions | 933.74M | Log In | Log In | Log In | Log In | Upgrade |
Biopharmaceutical and Diagnostic Solutions Growth | 8.50% | Log In | Log In | Log In | Log In | Upgrade |
Engineering | 170.29M | Log In | Log In | Log In | Log In | Upgrade |
Engineering Growth | -10.21% | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
Other | 6.45M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -12.98% | Log In | Log In | Log In | Log In | Upgrade |
Biopharmaceutical and Diagnostic Solutions Operating Profit | 165.64M | Log In | Log In | Log In | Log In | Upgrade |
Biopharmaceutical and Diagnostic Solutions Operating Profit Growth | 14.69% | Log In | Log In | Log In | Log In | Upgrade |
Engineering Operating Profit | 33.10M | Log In | Log In | Log In | Log In | Upgrade |
Engineering Operating Profit Growth | -10.51% | Log In | Log In | Log In | Log In | Upgrade |
Eliminations from Operating Profit | -37.59M | Log In | Log In | Log In | Log In | Upgrade |
Eliminations from Operating Profit Growth | 18.18% | Log In | Log In | Log In | Log In | Upgrade |
Other | 6.45M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -12.98% | Log In | Log In | Log In | Log In | Upgrade |
Other | 6.45M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | -12.98% | Log In | Log In | Log In | Log In | Upgrade |
Gross Income by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
Other | 3.12M | Log In | Log In | Log In | Log In | Upgrade |
Other | 3.12M | Log In | Log In | Log In | Log In | Upgrade |
Biopharmaceutical and Diagnostic Solutions Gross Profit | 268.78M | Log In | Log In | Log In | Log In | Upgrade |
Biopharmaceutical and Diagnostic Solutions Gross Profit Growth | 23.51% | Log In | Log In | Log In | Log In | Upgrade |
Engineering Gross Profit | 56.17M | Log In | Log In | Log In | Log In | Upgrade |
Engineering Gross Profit Growth | -48.85% | Log In | Log In | Log In | Log In | Upgrade |
Eliminations from Gross Profit | -22.63M | Log In | Log In | Log In | Log In | Upgrade |
Eliminations from Gross Profit Growth | -24.40% | Log In | Log In | Log In | Log In | Upgrade |
Other | 3.12M | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
EMEA | 667.83M | Log In | Log In | Log In | Log In | Upgrade |
EMEA Growth | - | Log In | Log In | Log In | Log In | Upgrade |
APAC | 96.24M | Log In | Log In | Log In | Log In | Upgrade |
APAC Growth | - | Log In | Log In | Log In | Log In | Upgrade |
North America | 308.95M | Log In | Log In | Log In | Log In | Upgrade |
North America Growth | - | Log In | Log In | Log In | Log In | Upgrade |
South America | 31.02M | Log In | Log In | Log In | Log In | Upgrade |
South America Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
Backlog | 853.00M | Log In | Log In | Log In | Log In | Upgrade |
Backlog Growth | - | Log In | Log In | Log In | Log In | Upgrade |